Andrew D. Seidman

15.9k total citations · 3 hit papers
211 papers, 11.1k citations indexed

About

Andrew D. Seidman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Andrew D. Seidman has authored 211 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 62 papers in Cancer Research. Recurrent topics in Andrew D. Seidman's work include Cancer Treatment and Pharmacology (135 papers), HER2/EGFR in Cancer Research (88 papers) and Breast Cancer Treatment Studies (56 papers). Andrew D. Seidman is often cited by papers focused on Cancer Treatment and Pharmacology (135 papers), HER2/EGFR in Cancer Research (88 papers) and Breast Cancer Treatment Studies (56 papers). Andrew D. Seidman collaborates with scholars based in United States, United Kingdom and Spain. Andrew D. Seidman's co-authors include Clifford A. Hudis, Larry Norton, Gabriella D’Andrea, Nancy T. Sklarin, Deborah Keefe, Virginia Paton, Paul Peter Rosen, Mary Kathryn Pierri, José Baselga and Steven Shak and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Andrew D. Seidman

202 papers receiving 10.7k citations

Hit Papers

Cardiac Dysfunction in th... 1996 2026 2006 2016 2002 1996 2000 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
    2002 1.1k citations Andrew D. Seidman, Clifford A. Hudis et al. Journal of Clinical Oncology profile →
  2. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
    1996 1.1k citations José Baselga, Debu Tripathy et al. Journal of Clinical Oncology profile →
  3. Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
    2000 596 citations José Baselga, Andrew D. Seidman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew D. Seidman United States 50 8.1k 2.5k 2.2k 2.2k 2.0k 211 11.1k
P. Fumoleau France 61 9.6k 1.2× 2.7k 1.1× 4.4k 2.0× 3.3k 1.5× 2.3k 1.1× 326 14.3k
Kristine Broglio United States 52 7.2k 0.9× 2.6k 1.1× 4.3k 2.0× 1.9k 0.9× 1.3k 0.6× 148 12.3k
Aňa Lluch Spain 55 10.3k 1.3× 2.5k 1.0× 6.1k 2.8× 4.1k 1.9× 2.7k 1.4× 306 14.7k
Carl Blomqvist Finland 67 7.6k 0.9× 3.7k 1.5× 4.0k 1.8× 4.0k 1.9× 1.4k 0.7× 331 14.0k
I. Craig Henderson United States 50 7.5k 0.9× 1.5k 0.6× 5.2k 2.4× 2.3k 1.1× 1.8k 0.9× 153 11.8k
Melody Cobleigh United States 39 10.5k 1.3× 2.8k 1.1× 3.8k 1.7× 4.3k 2.0× 3.0k 1.5× 131 14.7k
Sabino De Placido Italy 64 7.8k 1.0× 4.5k 1.8× 3.7k 1.7× 4.4k 2.0× 1.6k 0.8× 381 14.0k
Robert Paridaens Belgium 55 6.3k 0.8× 2.1k 0.8× 3.6k 1.7× 1.8k 0.8× 877 0.4× 307 9.9k
Maura N. Dickler United States 47 6.4k 0.8× 3.3k 1.3× 2.8k 1.3× 3.4k 1.6× 952 0.5× 166 10.5k
Christian Jackisch Germany 52 8.5k 1.0× 1.8k 0.7× 6.2k 2.8× 1.8k 0.8× 2.1k 1.0× 356 12.6k

Countries citing papers authored by Andrew D. Seidman

Since Specialization
Citations

This map shows the geographic impact of Andrew D. Seidman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew D. Seidman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew D. Seidman more than expected).

Fields of papers citing papers by Andrew D. Seidman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew D. Seidman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew D. Seidman. The network helps show where Andrew D. Seidman may publish in the future.

Co-authorship network of co-authors of Andrew D. Seidman

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew D. Seidman. A scholar is included among the top collaborators of Andrew D. Seidman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew D. Seidman. Andrew D. Seidman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferraro, Emanuela, Anne S. Reiner, Umberto Tosi, et al.. (2025). Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease. JAMA Network Open. 8(1). e2457483–e2457483. 1 indexed citations
2.
Hashmi, Atif A, Hannah Y. Wen, Melissa P. Murray, et al.. (2025). Clinicopathological features of microinvasive lobular carcinoma. Histopathology. 87(2). 235–245.
3.
Ferraro, Emanuela, Andrea V. Barrio, Daniel J. Kelly, et al.. (2024). Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab. npj Breast Cancer. 10(1). 96–96.
4.
Lebow, Emily S., Luke Pike, Andrew D. Seidman, et al.. (2023). Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases. JAMA Oncology. 9(12). 1729–1729. 28 indexed citations
5.
Anders, Carey K., Maria J. Sambade, Allison M. Deal, et al.. (2023). Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases. Breast Cancer Research and Treatment. 199(1). 99–107. 2 indexed citations
6.
Malani, Rachna, Martin Fleisher, Priya Kumthekar, et al.. (2020). Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal of Neuro-Oncology. 148(3). 599–606. 62 indexed citations
7.
Morikawa, Aki, Elisa de Stanchina, Elena Pentsova, et al.. (2019). Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. Clinical Cancer Research. 25(13). 3784–3792. 35 indexed citations
8.
9.
Bao, Ting, Andrew D. Seidman, Qing Li, et al.. (2018). Living with chronic pain: perceptions of breast cancer survivors. Breast Cancer Research and Treatment. 169(1). 133–140. 23 indexed citations
10.
Bao, Ting, et al.. (2016). Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Research and Treatment. 159(2). 327–333. 256 indexed citations
11.
Schwartz, Gordon F., Harry Bartelink, Harold J. Burstein, et al.. (2012). Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping. The Breast Journal. 18(4). 303–311. 11 indexed citations
12.
Vogelzang, Nicholas J., Sylvia Adams, Carol Aghajanian, et al.. (2011). Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology. 30(1). 88–109. 68 indexed citations
13.
Conlin, Alison & Andrew D. Seidman. (2008). Beyond Cytotoxic Chemotherapy for the First-Line Treatment of HER2-Negative, Hormone-Insensitive Metastatic Breast Cancer: Current Status and Future Opportunities. Clinical Breast Cancer. 8(3). 215–223. 27 indexed citations
14.
15.
Toppmeyer, Deborah, Andrew D. Seidman, Michaël Pollak, et al.. (2002). Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.. PubMed. 8(3). 670–8. 61 indexed citations
16.
Fornier, Monica, Mauro Risio, Catherine Van Poznak, & Andrew D. Seidman. (2002). HER2 testing and correlation with efficacy of trastuzumab therapy.. PubMed. 16(10). 1340–8, 1351. 56 indexed citations
17.
Poznak, Catherine Van, Lee K. Tan, Katherine S. Panageas, et al.. (2002). Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 20(9). 2319–2326. 65 indexed citations
18.
Poznak, Catherine Van & Andrew D. Seidman. (2002). Critical Review of Current Treatment Strategies for Advanced Hormone Insensitive Breast Cancer. Cancer Investigation. 20(sup2). 1–14. 10 indexed citations
19.
Baselga, José, Debu Tripathy, J. Mendelsohn, et al.. (1999). Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.. PubMed. 26(4 Suppl 12). 78–83. 229 indexed citations
20.
Baselga, José, Andrew D. Seidman, Paul Peter Rosen, & Larry Norton. (1997). HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.. PubMed. 11(3 Suppl 2). 43–8. 136 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. Fumoleau Breakdown of academic impact, for papers by Kristine Broglio Breakdown of academic impact, for papers by Aňa Lluch Breakdown of academic impact, for papers by Carl Blomqvist Breakdown of academic impact, for papers by I. Craig Henderson Breakdown of academic impact, for papers by Melody Cobleigh Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Robert Paridaens Breakdown of academic impact, for papers by Maura N. Dickler Breakdown of academic impact, for papers by Christian Jackisch
Rankless by CCL
2026